DE69231252T2 - Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten - Google Patents

Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten

Info

Publication number
DE69231252T2
DE69231252T2 DE69231252T DE69231252T DE69231252T2 DE 69231252 T2 DE69231252 T2 DE 69231252T2 DE 69231252 T DE69231252 T DE 69231252T DE 69231252 T DE69231252 T DE 69231252T DE 69231252 T2 DE69231252 T2 DE 69231252T2
Authority
DE
Germany
Prior art keywords
compound
autoimmune diseases
treatment
salicylic acid
substituted salicylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69231252T
Other languages
English (en)
Other versions
DE69231252D1 (de
Inventor
Hubert Agback
Leif Ahrgren
Thomas Berglindh
Martin Haraldsson
Lars-Inge Olsson
Goeran Smedegard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Publication of DE69231252D1 publication Critical patent/DE69231252D1/de
Application granted granted Critical
Publication of DE69231252T2 publication Critical patent/DE69231252T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
DE69231252T 1991-11-18 1992-11-04 Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten Expired - Fee Related DE69231252T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
PCT/SE1992/000758 WO1993010094A1 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids

Publications (2)

Publication Number Publication Date
DE69231252D1 DE69231252D1 (de) 2000-08-17
DE69231252T2 true DE69231252T2 (de) 2001-03-01

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231252T Expired - Fee Related DE69231252T2 (de) 1991-11-18 1992-11-04 Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten

Country Status (29)

Country Link
US (3) US5302718A (de)
EP (1) EP0613468B1 (de)
JP (1) JP3259915B2 (de)
KR (1) KR100253748B1 (de)
AT (1) ATE194597T1 (de)
AU (1) AU668528B2 (de)
CA (1) CA2123697C (de)
DE (1) DE69231252T2 (de)
DK (1) DK0613468T3 (de)
EE (1) EE03026B1 (de)
ES (1) ES2149780T3 (de)
FI (1) FI106857B (de)
GR (1) GR3034585T3 (de)
HU (2) HU221476B (de)
IL (1) IL103665A (de)
LT (1) LT3182B (de)
LV (1) LV10246B (de)
MX (1) MX9206647A (de)
MY (1) MY130169A (de)
NO (1) NO300805B1 (de)
NZ (1) NZ244998A (de)
PT (1) PT101068B (de)
RU (1) RU2124501C1 (de)
SE (1) SE9103397D0 (de)
SK (1) SK282080B6 (de)
TW (1) TW304944B (de)
UA (1) UA42869C2 (de)
WO (1) WO1993010094A1 (de)
ZA (1) ZA928864B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
WO1997010813A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
BR9708151A (pt) 1996-02-20 1999-07-27 Bristol Myers Squibb Co Processo para a preparaç o de bifenil isoxazol sulfonamidas
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
JP2003520758A (ja) 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド 抗エストロゲン耐性乳癌のｒｘｒモジュレーターを用いた処置
CA2367916A1 (en) 1999-03-19 2000-09-28 Ambarish Singh Methods for the preparation of biphenyl isoxazole sulfonamides
BR0013694A (pt) 1999-09-04 2002-05-21 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
JP2003508514A (ja) 1999-09-04 2003-03-04 アストラゼネカ アクチボラグ 化学的化合物
AU6715200A (en) 1999-09-04 2001-04-10 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
DE60115414D1 (de) * 2000-04-28 2006-01-05 Univ British Columbia N-heterosubstituierten salicylaten zur behandlung von krebs
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
EP1696915A1 (de) * 2003-12-19 2006-09-06 Pfizer, Inc. Benzolsulfonylamino-pyridin-2-yl derivate und verwandte verbindungen als hemmer von 11-beta-hydroxysteroid dehydrogenase typ 1 (11-beta-hsd-1) zur behandlung von diabetes und adipositas
EP1763353A1 (de) * 2004-06-29 2007-03-21 Warner-Lambert Company LLC KOMBINATIONSTHERAPIEN MIT BENZAMID-HEMMERN DES P2X<SB>7</SB> REZEPTORS
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
AU2007217750A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
US8314240B2 (en) * 2008-06-23 2012-11-20 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
CA2828212A1 (en) * 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibitors of bromodomains as modulators of gene expression
AU2016263564B2 (en) 2015-05-20 2019-12-05 Amgen Inc. Triazole agonists of the APJ receptor
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (de) 2016-11-16 2020-12-23 Amgen Inc. Triazol-furan-verbindungen als agonisten des apj-rezeptors
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3704122B1 (de) 2017-11-03 2021-09-01 Amgen Inc. Fusionierte triazolagonisten des apj-rezeptors
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
LV10246A (lv) 1994-10-20
DE69231252D1 (de) 2000-08-17
MY130169A (en) 2007-06-29
EE03026B1 (et) 1997-08-15
JPH07501330A (ja) 1995-02-09
ES2149780T3 (es) 2000-11-16
LV10246B (en) 1995-04-20
NO941799D0 (no) 1994-05-13
HU9401391D0 (en) 1994-08-29
JP3259915B2 (ja) 2002-02-25
EP0613468A1 (de) 1994-09-07
HU211163A9 (en) 1995-10-30
GR3034585T3 (en) 2001-01-31
SK282080B6 (sk) 2001-10-08
UA42869C2 (uk) 2001-11-15
AU668528B2 (en) 1996-05-09
ZA928864B (en) 1993-05-13
US5403930A (en) 1995-04-04
NO300805B1 (no) 1997-07-28
MX9206647A (es) 1993-05-01
NZ244998A (en) 1995-09-26
LTIP229A (en) 1994-09-25
NO941799L (de) 1994-06-22
TW304944B (de) 1997-05-11
SK54794A3 (en) 1995-02-08
PT101068B (pt) 1999-08-31
RU2124501C1 (ru) 1999-01-10
FI106857B (fi) 2001-04-30
KR100253748B1 (ko) 2000-05-01
DK0613468T3 (da) 2000-10-23
HUT69723A (en) 1995-09-28
WO1993010094A1 (en) 1993-05-27
CA2123697C (en) 2003-12-09
ATE194597T1 (de) 2000-07-15
HU221476B (en) 2002-10-28
AU2958992A (en) 1993-06-15
SE9103397D0 (sv) 1991-11-18
US5556855A (en) 1996-09-17
FI942289A (fi) 1994-05-17
CA2123697A1 (en) 1993-05-27
IL103665A0 (en) 1993-04-04
EP0613468B1 (de) 2000-07-12
US5302718A (en) 1994-04-12
FI942289A0 (fi) 1994-05-17
IL103665A (en) 1997-08-14
LT3182B (en) 1995-03-27
PT101068A (pt) 1994-02-28

Similar Documents

Publication Publication Date Title
DE69231252D1 (de) Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
PE58699A1 (es) Derivados de acido arilsulfonil hidroxamico
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
FI940414A0 (fi) Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
DE69418744D1 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
NO305799B1 (no) Nye kinolinderivater, farmas°ytiske preparater inneholdende slike derivater, deres anvendelse samt mellomprodukter
TH13794EX (th) ซับสทิทิวเทดซาลิไซลิคแอซิดชนิดใหม่

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee